Alkylating agents in bronchogenic carcinoma

Robert A. Green, Edward Humphrey, Henry Close, Mary Ellen Patno

Research output: Contribution to journalArticlepeer-review

214 Scopus citations


A large number of patients in a group of Veterans Administration Hospitals received a variety of alkylating agents in studies in which these agents were randomized with an inert compound. Intravenous cyclophosphamide, and possibly nitrogen mustard, had a slight favorable influence upon survival for all patients. A difference between the two agents was seen: patients with squamous cell carcinoma appeared to respond best to nitrogen mustard therapy and patients with small cell undifferentiated carcinoma to cyclophosphamide therapy, in fairly striking fashion. Over-all influences upon survival, however, were not remarkable.

Original languageEnglish (US)
Pages (from-to)516-525
Number of pages10
JournalThe American Journal of Medicine
Issue number4
StatePublished - Apr 1969
Externally publishedYes


Dive into the research topics of 'Alkylating agents in bronchogenic carcinoma'. Together they form a unique fingerprint.

Cite this